AstraZeneca Pharma India receives import and market permission from DCGI for Olaparib Film-Coated tablets

AstraZeneca Pharma India Limited has received Import and Market permission in Form CT-20 (Marketing Authorization) from the Drugs Controller General of India for Olaparib Film-Coated tablets 100 mg and 150 mg - additional indication.

Through this approval, Olaparib Film-Coated tablets 100 mg and 150 mg is additionally indicated as a monotherapy for treatment of adult patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene mutations (germline and/or somatic) who have progressed following a prior new hormonal agent.

The receipt of this Import and Market permission paves way for the launch of Olaparib FilmCoated Tablets 100 mg and 150 mg (Lynparza®) in India for the specified additional indication, subject to the receipt of related statutory approvals and licenses.

Shares of ASTRAZENECA PHARMA INDIA LTD. was last trading in BSE at Rs.3335.7 as compared to the previous close of Rs. 3336.4. The total number of shares traded during the day was 2633 in over 602 trades.

The stock hit an intraday high of Rs. 3369 and intraday low of 3318.3. The net turnover during the day was Rs. 8773668.

Source : Equity Bulls

Keywords